WHO recommends antibody combination therapy for specific new crown patients

Science and Technology Daily, Beijing, September 23 (intern reporter Zhang Jiaxin) On the 23rd, the World Health Organization's guideline development team published a recommendation in the British Medical Journal that it is recommended to use a combination of two antibodies-Cassie for two specific types of patients with new coronary pneumonia.
Retimab and Idvizumab treatment methods
.

The first category is non-severe new coronary pneumonia patients with the highest risk of hospitalization, such as unvaccinated, elderly or immunosuppressed patients; the second category is severe or critically ill patients with seronegative new coronary pneumonia who have no autoantibody reaction to new coronary pneumonia Patient
.

The first recommendation is based on new evidence from three trials
.

The second suggestion is based on data from the RECOVERY test
.

Casirizumab and Idvizumab are monoclonal antibodies.
When they are used together, they bind to the spike protein of the new coronavirus, thereby weakening the virus's ability to infect cells
.

The expert panel acknowledges that several costs and resource implications associated with this treatment may make this method challenging in low- and middle-income countries
.

The expert team also recognized that the emergence of new variants of the new coronavirus may weaken the effects of antibodies to Casirizumab and Idvizumab
.

However, the expert panel stated that given the proven benefits of the therapy for patients, “these recommendations should provide an incentive to involve all possible mechanisms to improve global access to interventions and related testing
.

This guideline supplements the previous recommendations, namely the use of interleukin-6 receptor blockers and systemic corticosteroids for severe or critically ill patients with new coronary pneumonia; the use of ivermectin, hydroxychloroquine and other drugs in the treatment of new coronary pneumonia is opposed